Vivos Therapeutics (VVOS) Cash from Investing Activities (2020 - 2026)
Vivos Therapeutics (VVOS) posted quarterly Cash from Investing Activities of -$18000.0 for Q1 2026, up 85.25% year-over-year from -$9716.8 in Q1 2025, and up 98.86% quarter-over-quarter from -$1.6 million in Q4 2025.
Vivos Therapeutics (VVOS) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Vivos Therapeutics (VVOS) has reported Cash from Investing Activities for 7 consecutive years, with -$18000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 85.25% year-over-year to -$18000.0; the TTM figure through Mar 2026 stood at -$7.4 million (down 1276.99% YoY), while the FY2025 annual figure was -$7.5 million, down 1225.0% from the prior year.
- Cash from Investing Activities advanced to -$18000.0 in Q1 2026 per VVOS's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $83000.0 in Q3 2025 and bottomed at -$5.9 million in Q2 2025.
- Historically, Cash from Investing Activities has averaged -$581705.9 across 5 years, with a median of -$165000.0 in 2023.
- On a YoY basis, Cash from Investing Activities climbed as much as 143.23% in 2025 and fell as far as 9743.33% in 2025.
- Vivos Therapeutics' Cash from Investing Activities stood at -$200000.0 in 2022, then grew by 17.5% to -$165000.0 in 2023, then changed by 0.0% to -$165000.0 in 2024, then sank by 858.18% to -$1.6 million in 2025, then soared by 98.86% to -$18000.0 in 2026.
- Business Quant data shows VVOS's Cash from Investing Activities at -$18000.0 in Q1 2026, -$1.6 million in Q4 2025, and $83000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn | -673.00 Mn |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn | -639.00 Mn |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn | -1.96 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -193.20 Mn |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn | 329.80 Mn |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn | -115.00 Mn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -22.08 Mn |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn | -108.50 Mn |
| 10 | Vivos Therapeutics | 4.96 Mn | 3.16 Mn | 2.95 Mn | -416,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18,000.00 |
| Mar 31, 2026 | -18,000.00 |
| Dec 31, 2025 | -1.58 Mn |
| Dec 31, 2025 | -1.58 Mn |
| Sep 30, 2025 | 83,000.00 |
| Sep 30, 2025 | 83,000.00 |
| Jun 30, 2025 | -5.91 Mn |
| Jun 30, 2025 | -5.91 Mn |
| Mar 31, 2025 | -122,000.00 |
| Mar 31, 2025 | -122,000.00 |
| Dec 31, 2024 | -165,000.00 |
| Dec 31, 2024 | -165,000.00 |
| Sep 30, 2024 | -192,000.00 |
| Sep 30, 2024 | -192,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Jun 30, 2024 | -60,000.00 |
| Mar 31, 2024 | -151,000.00 |
| Mar 31, 2024 | -151,000.00 |
| Dec 31, 2023 | -165,000.00 |
| Dec 31, 2023 | -165,000.00 |